Iloperidone, asenapine and lurasidone: a primer on their current status

Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines

(2016) Stephen M. Stahl   CNS SPECTRUMS

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

(2012) Stefan Leucht et al.   LANCET

Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system

(2012) Joanne Y.T. Leung et al.   PHARMACOLOGY & THERAPEUTICS

Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study

(2011) Herbert Y. Meltzer et al.   AMERICAN JOURNAL OF PSYCHIATRY

Agomelatine for the treatment of major depressive disorder

(2011) Regina M Carney et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials

(2011) Leslie Citrome et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia

(2011) Robert W. Buchanan et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder

(2011) Armin Szegedi et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration

(2011) John D. Elsworth et al.   NEUROPHARMACOLOGY

Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy

(2011) Ouissame Mnie-Filali et al.   NEUROPSYCHOPHARMACOLOGY

Therapeutic Options for Treatment-Resistant Depression

(2010) Richard C. Shelton et al.   CNS DRUGS

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

(2010) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism

(2010) Shikha Snigdha et al.   PSYCHOPHARMACOLOGY

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

(2009) S. M. Stahl et al.   ACTA PSYCHIATRICA SCANDINAVICA

Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management

(2009) Sanil Rege   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

The Serotonin-1A Receptor in Anxiety Disorders

(2009) Elena Akimova et al.   BIOLOGICAL PSYCHIATRY

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

(2009) Roger S McIntyre et al.   BIPOLAR DISORDERS

Lurasidone: a new drug in development for schizophrenia

(2009) Jonathan M Meyer et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

(2009) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

(2009) Yong Kee Choi et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Applicability of a Genetic Signature for Enhanced Iloperidone Efficacy in the Treatment of Schizophrenia

(2009) Simona Volpi et al.   JOURNAL OF CLINICAL PSYCHIATRY

Lurasidone in the Treatment of Acute Schizophrenia

(2009) Mitsutaka Nakamura et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Burden of Schizophrenia on Caregivers

(2009) A George Awad et al.   PHARMACOECONOMICS

5-HT1A receptor function in major depressive disorder

(2009) Jonathan Savitz et al.   PROGRESS IN NEUROBIOLOGY

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms

(2009) Olivia Frånberg et al.   PSYCHOPHARMACOLOGY

Asenapine effects in animal models of psychosis and cognitive function

(2009) Hugh M. Marston et al.   PSYCHOPHARMACOLOGY

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

(2009) Frank I. Tarazi et al.   SYNAPSE

The metabolic syndrome and schizophrenia

(2008) J. M. Meyer et al.   ACTA PSYCHIATRICA SCANDINAVICA

Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α2-adrenergic and D2 receptors in the rat brain

(2008) Ramez Ghanbari et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia

(2008) Andrew J. Cutler et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Long-Term Efficacy and Safety of Iloperidone

(2008) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Safety Profile of Iloperidone

(2008) Peter J. Weiden et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Efficacy of Iloperidone in the Treatment of Schizophrenia

(2008) Steven G. Potkin et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Asenapine induces differential regional effects on serotonin receptor subtypes

(2008) FI Tarazi et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

(2008) M. Shahid et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Asenapine Increases Dopamine, Norepinephrine and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus

(2008) Mei Huang et al.   NEUROPSYCHOPHARMACOLOGY

Differential regional and dose-related effects of asenapine on dopamine receptor subtypes

(2008) Frank I. Tarazi et al.   PSYCHOPHARMACOLOGY